Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Description

This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).

Conditions

Glioblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).

A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Condition
Glioblastoma
Intervention / Treatment

-

Contacts and Locations

Milwaukee

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Medical College of Wisconsin,

    Jennifer Connelly, MD, PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

    Study Record Dates

    2025-10-10